Biology and Management of Multiple Myeloma

ISBN-13: 9780896037069 / Angielski / Twarda / 2004 / 366 str.

James Berenson

Opis

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.

Recenzje

"...a well-organised and timely statement of pathophysiology...the breadth makes it useful as a starting place for students and primary-care practitioners, thereby justifying a place in the medical library." - Annals of Oncology

"Comprehensive and authoritative...offers both clinicians and researchers a thoroughly up-to-date understanding of the new biology that can be directly applied not only to future laboratory studies, but also to the optimal treatment of myeloma patients today." - Tumori

"...an authoritative, comprehensive and detailed interpretation of published studies related to myeloma." - Doody's Health Sciences Book Review Journal

Spis treści

Diagnosis of Multiple Myeloma Robert A. Kyle and Daniel E. Bergsagel Epidemiology of Multiple Myeloma and Related Disease Brian G. M. Durie Characterization of the Myeloma Clone Robert A. Vescio and James R. Berenson Oncogenesis of Multiple Myeloma Johannes Drach, Sonja Seidl, Jutta Ackermann, and Hannes Kaufmann Cytokines in Multiple Myeloma John De Vos and Bernard Klein Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle Tumor Burden: Staging and Prognostic Factors Douglas E. Joshua Treatment of Multiple Myeloma Meletios A. Dimopoulos and Robert A. Kyle Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma Jean-Luc Harousseau, Michel Attal, and Gary J. Schiller Allogeneic Transplantation in Multiple Myeloma Gösta Gahrton, Kenneth C. Anderson, and William Bensinger Immunological Approaches to Multiple Myeloma Hakan Mellstedt, Maurizio Bendandi, Anders Österborg, and Larry W. Kwak Remission Maintenance in Multiple Myeloma Heinz Ludwig and Niklas Zojer Myeloma Bone Disease James R. Berenson Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias Alan Solomon, Deborah T. Weiss, and Guillermo A. Herrera Pathogenesis and Treatment of Anemia Heinz Ludwig and Anders Österborg New Therapeutic Approaches to Myeloma Terry H. Landowski, William S. Dalton, and Sydney E. Salmon Index

Blurb

Bone marrow-based malignancy is becoming more commonplace. There have also been major advances in the diagnosis, pathogenesis, and treatment of this common tumor type. In Biology and Management of Multiple Myeloma, expert physicians and clinical researchers summarize and explain the recent advances in the biology and treatment of this common B-cell tumor. On the biological side, the authors review the many important, clinically relevant discoveries that have been made in the last few years. They show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents. The role of high-dose therapy is also discussed, along with the treatment of such complications as renal disease, anemia, and bone disease.
Comprehensive and authoritative, Biology and Management of Multiple Myeloma offers both clinicians and researchers a thoroughly up-to-date understanding of the new biology that can be directly applied not only to future laboratory studies, but also to the optimal treatment of myeloma patients today.